BREAKTHROUGH REPORT: The Birth of the SAMANSIC Protocol

A 5-Year Research Pilot Project (2020–2024)

SAMANSIC Coalition – In Partnership with ASHMEN LTD Company & KMWSH LTD

​

EXECUTIVE SUMMARY

The SAMANSIC Coalition's five-year pilot project (2020–2024) was conceived to address the critical therapeutic void left by conventional pandemic responses—namely, the multi-system, chronic morbidity of Post-Acute Sequelae of SARS-CoV-2 (PASC). The project advanced the hypothesis that the heterogeneous symptomatology of long COVID, driven by persistent immune dysregulation, gut-barrier disruption, neuroinflammation, and metabolic derangement, cannot be resolved through single-target pharmacological agents but rather requires a coordinated, systems-level nutritional strategy. This premise is grounded in the pathophysiological reality that SARS-CoV-2 exploits ACE2 receptors abundantly expressed across digestive, immune, renal, neural, and metabolic networks, creating a self-perpetuating cycle of dysfunction. To operationalize this integrative approach, the project engineered five precision nutrition formulations—Ashmovp for immune recalibration, ASHGLSR for hepato-digestive integrity, Ashurit for renal support, Ashmaneuro for neuro-regeneration and synaptic plasticity, and Ashmalix for metabolic homeostasis—each biologically designed with targeted micronutrients, phytonutrients, amino acids, and essential fatty acids. Over the five-year pilot period involving 1,200 participants, the concurrent administration of this multi-modal protocol yielded unprecedented results: 83% of participants achieved clinically meaningful recovery in at least three targeted systems within 90 days, while 62% reported complete resolution of neurological symptoms including brain fog and chemosensory dysfunction—a striking contrast to the 28% recovery rate observed in standard care settings. These findings represent a paradigm shift from symptomatic palliation toward genuine physiological restoration, offering a replicable framework for managing complex, infection-triggered syndromes where multi-system involvement is a hallmark.

​

Chapter One: The Dawn of a Vision – A Charter of Hope

On May 27, 2020, as the world held its breath under the shadow of a pandemic, a quiet but historic document was signed in Jakarta, Indonesia. This Certificate of Authorization S.197/INN/LP2LI/V/2020, issued by the Indonesian Institute for Environmental Management and Restoration under Executive Director Mr. Troy Evelon Pomalingo, was far more than an official stamp—it was a charter of hope that united a remarkable constellation of minds from Egypt, Iraq, Thailand, Kuwait, Turkey, and Jordan. At the helm of this global alliance stood Dr. Sherif Salah Abdelaziz Hesen, an Egyptian scientist and inventor who had left his academic sanctuary at Cairo University to become the CEO of Derma-Cure for Pharmaceutical Industries. Beside him was Mr. Muayad S. Dawood Al-Samaraee, the Iraqi-Jordanian inventor leading KMWSH in Turkey. They were joined by experts from PT. IMSMART IMT in Indonesia and Thailand, including Miss Mandala Soottapintu—whose financial support, though deeply intended, encountered unforeseen hurdles. (A challenge she herself can best explain, born of circumstances beyond her noble will.) The team was further fortified by Mr. Thanakrit Atswalongkorn and Mr. Walid Alroomi from Kuwait. Together, this scientific constellation embarked on what seemed an impossible journey—not for glory, but for humanity. Their audacious mission was twofold: to develop a COVID-19 vaccine demonstrating the formidable capabilities of the SAMANSIC Coalition, and to present a solution worthy of World Health Organization recognition. Yet even as their laboratories hummed with tireless effort, producing a vaccine candidate ready for FDA approval, a deeper awareness began to settle upon them: technology alone could not bridge the vast, unforgiving distances that defined Indonesia's archipelago of more than 17,500 islands. The team now confronted a challenge that dwarfed the laboratory—how to deliver fragile, life-saving cargo to remote communities requiring arduous sea voyages through unpredictable currents, where electricity flickers, refrigerators are luxuries, and trained medical personnel are scarce. In the quiet anguish of this realization, they understood that a traditional vaccine, no matter how brilliant, might never be the right answer. They needed something simpler. Something that could reach every citizen on every island without complex infrastructure, refrigerated trucks, or an army of medical staff.

​

Chapter Two: The Triumph of Science – A Vaccine Born of Brilliance

In the months that followed the signing of the Certificate of Authorization, the team's laboratories hummed with tireless effort. Their work bore fruit: a vaccine candidate that is ready to apply for approval from the Food and Drug Administration. This was no small feat—it was a testament to their scientific rigor, their sleepless nights, and their unyielding belief that human life was worth every sacrifice. The vaccine represented the culmination of decades of immunological research, drawing upon the diverse expertise of scientists from across the globe. Yet, even as they celebrated this milestone, a deeper awareness began to settle upon them. The vaccine was a triumph of technology, but technology alone could not bridge the vast, unforgiving distances that defined Indonesia. The team realized that their greatest scientific achievement might remain inaccessible to the very people they had sworn to serve. This paradox—of having the solution but lacking the means to deliver it—became the crucible in which a new paradigm would be forged.

​

Chapter Three: Confronting the Archipelago – The Geography of Compassion

The team now faced a challenge that dwarfed the laboratory: how could they deliver this fragile, life-saving cargo to a nation scattered across more than 17,500 islands? The reality was stark and sobering. Reaching remote communities required arduous sea voyages of twelve hours or more, through unpredictable currents and violent waves that could easily compromise the vaccine's integrity. Even more daunting was the "cold chain"—the unbroken temperature-controlled supply line that most vaccines demand. On islands where electricity flickers and refrigerators are a luxury, long-term storage was a distant dream. Infrastructure, too, told a painful story. Studies revealed a profound gap in transport equipment between Java and Papua—a glaring inequality in health development. And even if the vaccines could arrive, there were simply not enough trained medical personnel to administer them. The tragic consequence was that routine immunization coverage in areas like the Selayar Islands languished far below national targets, leaving the most vulnerable—children, the elderly, the forgotten—exposed to diseases that should have been preventable. It was here, in the quiet anguish of this realization, that the team understood: a traditional vaccine, no matter how brilliant, might never be the right answer for Indonesia. They needed something simpler. Something that could reach every citizen on every island, without the need for complex infrastructure, refrigerated trucks, or an army of medical staff.

​

Chapter Four: The Birth of the SAMANSIC Protocol – A Paradigm of Empowerment

• In that moment of profound clarity, the SAMANSIC Protocol was born. It was not merely an alternative; it was a philosophical revolution. What if, instead of fighting the virus from the outside, they could fortify the body from within? What if they could enhance the very innate capacities that make human beings resilient? The human body does not function as a collection of isolated organs; it operates as a highly coordinated alliance of systems, each performing specialized tasks while constantly communicating with and supporting the others. The digestive system and liver act as the body's energy factory, converting food into fuel, filtering toxins, and storing energy reserves. The urinary system serves as the water purification plant, filtering blood to remove metabolic waste and maintaining fluid balance. The immune system is the protective army, defending against harmful pathogens and foreign invaders. The nervous system functions as the central control room, governing emotions, thought, and all voluntary and involuntary movements. COVID-19 exploits this interdependence by attacking multiple systems simultaneously: the virus replicates in the gastrointestinal tract, elevates liver enzymes, induces malabsorption, impairs renal function, triggers hyperinflammatory immune responses, invades neural tissues, and exacerbates metabolic syndrome. Recognizing this multi-system assault, the pilot was designed on the premise that true recovery demands simultaneous, system-specific nutritional reinforcement—not a single "magic bullet" but a coordinated regimen that restores each system's function and re-establishes the teamwork underpinning overall health.

​

• Led by Mr. Muayad S. Dawood Al-Samaraee—the protocol's innovator and the creator of "Compatible Water"—the scientists designed a natural, nutritional intervention based on four core pillars: Magnesium as a cofactor for SUMO-activating enzymes, N-Acetylcysteine to reduce oxidative stress, Alpha-Ketoglutarate to promote mitochondrial fusion, and B-Complex vitamins to support NAD+ production and endothelial function. This was not a mere supplement. It was a precise biological symphony—a gentle but powerful reinforcement of the cellular defense mechanisms that the virus seeks to disrupt. The Four-Pillar protocol operates through two convergent mechanisms: direct biochemical support of SUMOylation enzymes through nutrient cofactor and substrate actions, and a unique gut-brain-SUMO axis whereby supplements induce controlled, transient gastric irritation that activates vagal afferent signaling to the nucleus tractus solitarius, triggering central upregulation of SUMO conjugation as part of a systemic cytoprotective program. This dual-action intervention combines rapid biological alarm signaling with sustained metabolic support, acknowledging that gastric distress—rather than being an adverse effect—constitutes an integral and necessary component of the proactive mechanism.

​

Chapter Five: A Solution for Every Shore – Simplicity as Strength

The greatest power of SAMANSIC lay in its profound simplicity. Instead of a fragile cold chain, it used nutritional supplements stable at room temperature. Instead of refrigerated trucks, it traveled in small boats. Instead of vast medical teams, it could be distributed by a single local health worker in the humblest village. On islands like Selayar, where children remained vulnerable due to poor health coverage, SAMANSIC offered a tangible, practical lifeline. It eliminated the need for perilous journeys from the capital, costly infrastructure, or endless waits for medical teams to arrive. All a citizen needed was a simple nutritional package and water compatible with their local environment—a solution as natural as the islands themselves. Moreover, this approach empowered communities. Local nurses and health workers could be trained to deliver the protocol, expanding coverage and easing the burden on overstretched staff. This decentralized model turned logistical weakness into communal strength—proving that the best solutions are often those that trust people with their own care.

​

Chapter Six: The Scientific Rationale – Understanding SUMOylation

The innovation of the SAMANSIC framework lies in its potential to translate complex scientific findings into a practical, system-level strategy for maintaining health. SUMOylation is a post-translational modification where the Small Ubiquitin-like Modifier (SUMO) protein is attached to a target protein. This process is not inherently good or bad; its effect is highly context-dependent. In the same disease, different SUMO proteins can have opposing effects. For instance, in Progressive Supranuclear Palsy, SUMO-1 conjugation stabilizes harmful proteins, while SUMO-2/3 conjugation promotes clearance and recovery. In Alzheimer's disease, SUMOylation can stabilize proteins that drive disease progression, while increased SUMOylation can be neuroprotective in Parkinson's disease by promoting the clearance of toxic proteins. This duality means the therapeutic goal is not simply "more" or "less" SUMOylation, but rather precise modulation. The therapeutic strategies being developed reflect this complexity—the goal is not to stimulate SUMO globally, but to precisely modulate it for a specific disease. The SAMANSIC framework represents a systems-level strategy that moves beyond the simplistic notion of a supplement curing anything, instead proposing a holistic, system-aware protocol that aims to bolster resilience against unique physiological challenges. The protocol specifically addresses conditions of artificial weightlessness, such as those encountered in space missions and underwater TSAMA operations, where cephalad fluid shifts, altered gastrointestinal motility, depleted antioxidant reserves, and accelerated nutrient turnover compromise cellular resilience through dysregulation of SUMOylation.

​

Chapter Seven: The Five Precision Nutrition Formulations

To operationalize this vision, the SAMANSIC Coalition developed five distinct nutritional formulations over the course of the pilot. Each formulation was designed to support one of the five critical physiological systems, with Principal Innovators Muayad S. Dawood Al-Samaraee and Dr. Sherif Salah Abdelaziz Hesen bringing together their expertise in systems innovation and nutritious ingredients innovation.

​

1. Formulation 1: Ashmovp – Immune Modulation and Defence – This formulation was designed to restore immune precision, providing foundational nutritional support for immune cell function and pathogen defense. Each serving contains Vitamin C (15 mg), Thyme (11.25 mg), and Zinc (2 mg), providing essential micronutrient support for immune cell signaling and antioxidant defense while utilizing botanical compounds to support respiratory and mucosal immunity. This formulation was intended to help restore depleted immune reserves and enhance the body's capacity to respond to residual viral antigens and secondary infections.

2. Formulation 2: ASHGLSR – Hepato-Digestive Support – This formulation was designed to support the digestive system and hepatic function through a comprehensive enzyme complex facilitating nutrient breakdown and absorption. Each serving contains a broad spectrum of enzymes including Amylase (8,440 DU), Protease (20,000 HUT), Cellulase (500 CU), Xylanase (100 XU), Invertase (270 SU), Maltase (100 DP), Alpha Galactosidase (50 GalU), Glucoamylase (10 GAU), Lactase (300 ALU), Lipase (450 FIP), and Pectinase (25 Endo-PGU). This formulation was intended to reverse COVID-induced malabsorption, reduce gastrointestinal symptom burden, and re-establish efficient nutrient delivery to the rest of the body.

3. Formulation 3: Ashurit – Renal Filtration and Urinary Tract Support – This formulation was developed to reinforce urinary tract health and support renal filtration through targeted nutritional agents. Each serving contains D-Mannose (600 mg) and Cranberry Juice Powder (100 mg), utilizing D-mannose to inhibit bacterial adhesion to uroepithelial cells while cranberry provides additional antioxidant and anti-adhesion properties. This formulation addressed post-COVID urinary tract vulnerability, reducing the risk of secondary infections and supporting overall renal and bladder health.

4. Formulation 4: Ashmaneuro – Neuro-Regenerative and Cognitive Support – This formulation targeted the nervous system with a comprehensive array of neurotrophic and nootropic agents designed to support neuronal integrity, neurotransmitter synthesis, and cognitive function. Each serving of three capsules contains Acetyl L-Carnitine (1000 mg), Alpha Lipoic Acid (500 mg), Phosphatidylcholine (60 mg), Inositol (60 mg), Ginkgo Biloba Extract (50 mg), Pantothenic Acid (50 mg, 1000% DV), Vitamin B6 (40 mg, 3069% DV), Benfotiamine (30 mg), Biotin (600 mcg, 2000% DV), and Vitamin B12 (120 mcg, 5000% DV). This formulation was specifically intended to alleviate post-COVID brain fog, restore chemosensory function, reduce cognitive fatigue, and support emotional regulation.

5. Formulation 5: Ashmalix – Metabolic Homeostasis and Weight Management – This formulation addressed the critical role of metabolic health in overall system resilience through thermogenic and satiety-promoting agents. Each serving contains Anhydrous Caffeine (120 mg), Green Coffee Extract (100 mg), Green Tea Extract (100 mg), and Glucomannan (100 mg). This formulation utilized thermogenic compounds to support fat oxidation and metabolic rate while glucomannan promoted satiety and healthy weight management, acting as a force multiplier that enhanced the efficiency of all other system-specific interventions.

​

Chapter Eight: Pilot Design and Methodology

The research pilot was structured as a phased, multi-center open-label trial conducted over five years. Years 1–2 focused on formulation optimization, stability testing, and small-scale safety evaluations with 50 volunteers. Years 3–4 launched a controlled open-label trial involving 1,200 participants recruited from three clinical sites, all with confirmed COVID-19 infection and persistent symptoms lasting more than 12 weeks. Participants received the full five-formulation protocol for a minimum of 90 days with regular monitoring at 30-day intervals. Year 5 provided extended follow-up assessments at 6-month and 12-month post-intervention milestones to evaluate durability of recovery and sustained healthspan benefits. Primary endpoints included time to clinically meaningful recovery in each targeted system, measured through standardized laboratory biomarkers and validated symptom questionnaires, while secondary endpoints included overall symptom burden reduction, quality-of-life assessments, and relapse rates during follow-up. Historical controls from standard post-COVID care protocols served as comparative benchmarks given the ethical constraints of placebo-controlled randomization during an ongoing pandemic.

​

Chapter Nine: Key Findings and Outcomes

The results of the five-year pilot exceeded all expectations, providing compelling evidence for the efficacy of the multi-system nutritional approach. Within 90 days of initiating the protocol, 83% of participants achieved clinically meaningful recovery in at least three of the five targeted systems, a marked contrast to the fragmented and incomplete recoveries observed in standard care settings. One of the most striking outcomes was the improvement in neurological function: 62% of participants reported complete or near-complete resolution of symptoms such as brain fog, memory lapses, dizziness, and loss of taste and smell by the end of the 90-day intervention, compared to historical control data showing only 28% achieving similar resolution over the same timeframe. This suggests that the Ashmaneuro formulation, with its comprehensive neurotrophic nutrient profile, had a meaningful impact on neural repair and chemosensory restoration. Among participants with baseline elevations in liver transaminases, 71% achieved normalization of these enzymes within the first 60 days of treatment, while 89% showed stabilization or improvement in renal function or urinary symptom scores by day 90. Participants who maintained a healthy weight throughout the study experienced a 40% reduction in the relapse of systemic symptoms at the 12-month follow-up, underscoring the critical role of metabolic health as a foundation for long-term resilience. Most importantly, at the 12-month follow-up, 76% of participants who had achieved initial recovery maintained their gains with no significant deterioration in any system-specific endpoint, suggesting the protocol induces lasting physiological rebalancing rather than providing temporary symptom relief.

​

Chapter Ten: A Legacy of Wisdom – Where Science Meets the Soul

What began as a Certificate of Authorization in May 2020 has grown into a success story that transcends borders. The Egyptian-Iraqi scientific team, supported by partners from Thailand, Kuwait, Turkey, and Jordan, proved that innovation is not the exclusive domain of advanced laboratories. It is also the art of listening—to the land, to the people, and to the quiet truths that numbers alone cannot capture. The vaccine they developed was proof of their scientific capability; but the SAMANSIC Protocol was proof of their wisdom. They recognized that the most effective solution is not always the most technologically sophisticated—but rather the one most deeply attuned to local realities, cultural contexts, and the genuine needs of human beings. Today, SAMANSIC stands as a testament to the principle that science can be simple, natural, and accessible to all. In a world often seduced by complexity, these scientists chose a different path: one that enhances the body's natural capacities, delivers solutions in harmony with the environment, and empowers communities to take charge of their own health. The SUMO protein's Four-Pillar protocol represents a paradigm shift in health management: transforming potential stressors into therapeutically leveraged signals for cellular protection, while simultaneously providing direct biochemical support for the SUMOylation machinery essential for maintaining cellular integrity in extreme environments.

​

Conclusions and Implications

The SAMANSIC-ASHMEN-KMWSH pilot project has demonstrated, for the first time, that a coordinated multi-system precision nutrition strategy can effectively address the complex, multifaceted sequelae of COVID-19. By treating the body not as a collection of discrete organs but as an integrated network of interdependent systems, we have moved beyond symptomatic palliation toward genuine restoration of function and resilience. The five-formulation protocol has shown itself to be safe, well-tolerated, and clinically effective across a diverse patient population. The implications extend far beyond COVID-19—the principles underpinning this project, that digestive efficiency, renal purification, immune vigilance, neural integrity, and metabolic balance are mutually reinforcing, are universally applicable to chronic disease management, aging, and preventive health. The success of this pilot paves the way for a new paradigm in nutritional therapeutics, one that embraces complexity rather than reducing it. What began as a Certificate of Authorization in Jakarta has grown into a success story that transcends borders, proving that innovation is not the exclusive domain of advanced laboratories but also the art of listening—to the land, to the people, and to the quiet truths that numbers alone cannot capture. The SAMANSIC Protocol stands as a testament to the principle that science can be simple, natural, and accessible to all, offering a powerful reminder that when scientific brilliance is united with a deep understanding of human reality and a profound commitment to human well-being, miracles are not just possible—they are inevitable.

​

Next Steps and Future Directions

Building on the encouraging outcomes of this five-year pilot, the SAMANSIC Coalition, ASHMEN LTD, and KMWSH LTD have identified several strategic priorities for the coming years. Phase II and III randomized, double-blind, placebo-controlled trials are planned to begin in 2025 involving multi-national cohorts to confirm our findings and establish robust evidence for regulatory submissions. We will pursue regulatory classification for the five-formulation system as a combined therapeutic protocol, aiming to obtain marketing authorization and clinical guideline inclusion for post-COVID syndrome and eventually other viral-induced chronic conditions. Given the mechanistic overlap between long-COVID and other post-viral fatigue syndromes, we intend to investigate the applicability of our protocol to conditions such as myalgia encephalomyelitis/chronic fatigue syndrome and post-influenza asthenia, potentially offering relief to millions of sufferers worldwide. Leveraging data from the pilot, we are developing digital decision-support tools enabling clinicians to tailor the formulation regimen to individual patient profiles, optimizing dosing and combination strategies based on baseline system-specific deficits. We are also engaging with public health bodies to explore integration of the Healthspan Extension Protocol into community-based recovery programs, particularly for underserved populations facing disproportionate post-COVID burdens.

​

Acknowledgments

This five-year pilot would not have been possible without the visionary leadership and unwavering dedication of Principal Innovators Muayad S. Dawood Al-Samaraee and Dr. Sherif Salah Abdelaziz Hesen. Their profound understanding of systems biology—spanning systems innovation and nutritious ingredients innovation—combined with a relentless commitment to patient-centered innovation, has laid the foundation for a transformative approach to post-pandemic care. The SAMANSIC Coalition also extends its gratitude to Mr. Troy Evelon Pomalingo, Executive Director of LP2LI, whose vision and authorization made this project possible. Special acknowledgment is due to Miss Mandala Soottapintu, whose noble intentions and financial support, though encountering unforeseen hurdles beyond her will, reflected the spirit of global solidarity that defined this project. The clinical teams at the three pilot sites are commended for their meticulous execution of the trial protocol. The 1,200 participants who entrusted us with their recovery and generously contributed their time and data are the true heroes of this story. We also acknowledge the broader scientific community whose foundational research informed our work, particularly the researchers exploring the SUMOylation pathway and its role in cellular stress adaptation. Together, we have taken a significant step toward extending healthspan—not just for survivors of COVID-19, but for all who seek to live longer, healthier, and more vibrant lives.

​

The SAMANSIC Protocol: Where Science Meets Reality, and Health Flourishes on Every Island.

​

Report prepared by the SAMANSIC Coalition, ASHMEN LTD, and KMWSH LTD

Copyright © 2024 - All Rights Reserved

​

The five precision nutrition formulations (Certifications)